Greg Cathcart: Catalyst for Continuous Growth in the U.S.

Greg Cathcart, SVP, NNIT US

Greg Cathcart, SVP, NNIT US

As NNIT expands its presence in the United States, particularly with the anticipated integration of Excellis Health Solutions (Excellis), Greg Cathcart, Head of Excellis, has assumed the lead role of Senior Vice President to accelerate growth and advance the market position in the US.

In the past five years, NNIT has substantially expanded its US presence through organic growth and strategic mergers and acquisitions (M&A). Excellis, acquired in 2020 to enhance NNIT’s strategic consulting services portfolio, is now being integrated to expedite NNIT’s growth journey in the US market.

End-to-end life sciences consulting services for every step of the value chain

The new NNIT US organization will employ over 200 professionals and a range of subject matter experts in almost all areas of life sciences operations while offering solutions spanning the life sciences value chain, including Regulatory, R&D, Quality & Compliance, Manufacturing & Supply Chain and Data & Digital, with plans to expand the solutions portfolio further.

“From the beginning, we saw great potential for synergies. The combination of NNIT’s end-to-end life sciences value chain consultancy services with Excellis’ specific focus on serialization and track & trace globally is second-to-none. It is time to take our union to the next level, becoming one company and taking full advantage of those synergies to unlock further growth. I am excited and proud to be heading up this new era for NNIT and our many talented people in the US,” comments Greg Cathcart, in his new role as SVP, Head of NNIT US.

Supporting future growth

As the integration of Excellis gets underway, and complimentary teams, experts and professionals are coming together to create a unified culture, 2024 is poised to be a significant year for NNIT US. At the same time, to support plans to grow both top and bottom lines, NNIT US will onboard up to 25 new professionals to bolster an already dynamic team.

“We operate in a very meaningful space empowering those who change lives, and we’re growing beyond our long-serving and loyal teams, so it’s an exciting time to join NNIT US. We’re constantly enhancing our diverse workplace where we use our domain expertise to create results for our customers. We’re looking for individuals with an appetite for new adventures and the opportunity to liberate their talent and make a mark,” Greg Cathcart says.

Organic growth and M&A

In accordance with the NNIT Group strategy, a strong focus is on continued organic and acquired growth in the US, specifically the ambition is to grow the solutions portfolio and add further areas of strategic consulting expertise in support of the life sciences value chain via strategic M&A.

“We’re absolutely expecting to reap the benefits from the combined NNIT and Excellis teams and expand our offering to the life sciences industry. We’re going to thoroughly analyze our current solution portfolio with a view to making our existing services more robust. There’s a lot of potential for cross-pollination here – and we’re all very excited about our prospects,” Greg Cathcart finishes.

About Greg Cathcart

A significant portion of Greg Cathcart’s early career was spent at Johnson & Johnson in manufacturing and supply chain roles. In 1991, he made a transition to a tech company specializing in ERP solutions (QAD Inc) for pharmaceutical and medical device companies. In 2002, Greg joined SAP where he led the global life science practice for five years. His inherent entrepreneurial spirit eventually led him to establish Excellis in 2008. He sold Excellis to NNIT in 2020 – and having over-performed on the earnout agreement, he now continues as Senior Vice President, Head of NNIT US.

Three Dates for Your EU-FMD 2025 Calendar

Mark your 2025 calendars (yes, you read that right)- Christoph Krähenbühl, Excellis’ Senior Director/Executive Subject Matter Expert, discusses the three dates you should be aware of for your EU-FMD 2025 calendar.

“As we are approaching the end of the year 2023, it is time to look towards not 2024, but the year 2025, which will bring in several notable changes to the EU-Falsified Medicines Directive (FMD) systems and processes that will require the attention of all Marketing Authorisation Holders (MAHs) selling medicines in Europe.”

Read Here

Luke List Likes Winning… and So Do We!

Victory is Sweet

Luke List, 38, emerged victorious in the 2023 Sanderson Farms Championship. In a nail-biting finish, List snagged the title in a 5-man playoff.

With a final round of 70, List sank a birdie putt from just inside 45 feet on the first sudden-death playoff hole, the par-4 18th, placing him in first and securing his second PGA TOUR victory.

Excellis Health Solutions has been a proud supporter of List for years and we congratulate him on this incredible achievement!

New White Paper on Dispensers & DSCSA Regulations Published

The Importance of DSCSA to Dispensers

The Drug Supply Chain Security Act (DSCSA) is a United States federal law that was enacted in 2013 in order to prevent counterfeit and stolen drugs from entering the legitimate pharmaceutical supply chain.

The DSCSA has a number of provisions that aim to improve the security of the drug supply chain in the United States. One of the key provisions is to create an interoperable system for tracking and tracing prescription drugs. This system will allow the FDA to identify and track drugs as they move through the pharmaceutical supply chain from the manufacturer to the dispensers and ultimately to the customer.

This white paper was written by Excellis Health Solutions’ Stephen Kovary, RPh (Executive Vice President) and Caitrin O’Shea (Senior Strategy Consultant).

Read the White Paper

Excellis’ CEO featured in NNIT white paper “The Factory of the Future is Fully Integrated”

In collaboration with our parent company NNIT and their group companies SL Controls and Excellis Health Solutions comes the very first white paper. It gives a very holistic view of the digitalization of the complete production process and supply chain integration.

What is this white paper about?
In the future pharma production, it will be essential to manage increasingly complex production processes and manufacturing micro-batches tailored to more specific therapies and patient groups.

The enabler is a connected factory, where data and information can flow freely both within the production site and externally. This requires a fully digitized and integrated process and control equipment across all areas of operation including supply chain integration.

This whitepaper shows you

  • Challenges and the potential benefits of an integrated factory
  • Best practices and solutions for making it happen
  • Common mistakes and pitfalls


Excellis’ Managing Consultant Featured in Brand Protection Book

Excellis’ Managing Consultant in SME, Sean O’Hearen, has written two chapters in Professor Jeremy Wilson’s book, Brand Protection and the Global Risk of Product Counterfeits: A Total Business Solution Approach!

According to Professor Wilson, the book is “Based on substantial field research and practice, this book provides a framework for building and advancing brand protection programs that are strategic, comprehensive, and evidence based.”

The book will be released globally on July 19, 2022.

For more information, click here.

Excellis and NNIT to participate in DIA Global Annual Meeting 2022

Excellis Health Solutions and parent company NNIT will be participating in the DIA Global Annual Meeting 2022 in Chicago, IL.

Brook Casselberry, AVP, US Life Sciences Advisory and Consulting is chairing the session “Data Integrity Across the Production Lifecycle” and Excellis’ Chrisoph Krahenbuhl, Senior Director will be a speaker in this session.

The presenters in this session will discuss data integrity in product design, clinical development, and supply chain.

Learn More

Jazz Pharmaceuticals Health Check and Brand Risk Assessment Case Study

In an age where the protection, security and traceability of medicines is constantly under the spotlight, pharma companies of all sizes must rise to the challenge of developing watertight systems and processes across their entire operation.

This case study explores how a comprehensive risk assessment service from Excellis Health Solutions has enabled Jazz Pharmaceuticals’ supply chain teams to assess their traceability compliance readiness, strengthen their brand protection program, and identify opportunities to exemplify industry best practice.

With patient safety a critical concern, complying with global track and trace mandates and managing and mitigating risk is an essential component of safe and effective pharmaceutical supply management.

This study explains how the Excellis health check and brand risk assessment can help pharma firms minimize security challenges, and is available to download from our knowledge base.

Download Now